Elicio Therapeutics, Inc. 8K

Elicio Therapeutics reported Phase 2 AMPLIFY-7P data showing ELI-002 7P missed its primary DFS endpoint in ITT mKRAS+ PDAC but demonstrated a clinically meaningful signal in R0-resected patients, guiding a planned, funding-dependent Phase 3 program and further regulatory engagement.

Elicio Therapeutics furnished an investor presentation on the Phase 2 AMPLIFY-7P trial of its ELI-002 7P immunotherapy in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma, disclosing that while the randomized study did not meet its primary disease-free survival endpoint in the overall intent-to-treat population, post-hoc analyses showed early separation of DFS curves during active treatment, a stronger treatment effect and statistically significant signal in completely resected (R0) patients, robust mKRAS-specific T-cell responses associated with improved DFS, and a favorable safety profile with fewer severe adverse events versus observation; based on these findings, the company outlined a precision Phase 3 development strategy focused on R0-resected patients with extended dosing, and stated that advancing to Phase 3 and pipeline expansion will depend on regulatory alignment and funding.

Filing Facts

CIK

1601485

Ticker

-

Form

8K

Source Type

sec

Accession

0001601485-26-000046

Alert Tier

6